Latest
AD HOC NEWS Guidance
News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 1–36
- Matches
- 119
- Sources here
- 11
- Companies here
- 1
Search results
Stored financial headlines
Active search
119 matching headlines
Ticker or company: BRMMain companies and provider mentions
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
3 Reasons to Sell BMY and 1 Stock to Buy Instead
3 Reasons to Sell BMY and 1 Stock to Buy Instead Even though Bristol-Myers Squibb (currently trading at $66.44 per share) has gained 6.6% over the last six months, it has lagged the S&P 500's 12.3% return during that period. This might have investors …
BRM
main company
Sharemaestro market context
Trend signal active
52 weeks +49.8% · Next-week setup positive 56.0%
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
New single-arm, open-label data extend the body of evidence supporting consistent clinical benefit and safety with Camzyos, adding to the longest-running clinical development experience for a cardiac myosin inhibitor (CMI) in symptomatic oHCM Additional presentations at ESC Congress build upon the established effectiveness and …
BRM
main company
Sharemaestro market context
Trend signal active
52 weeks +49.8% · Next-week setup positive 56.0%
Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors
Bristol Myers Squibb (NYSE: BMY) was created via the combination of companies founded in 1858 and 1887. It has a proven history of survival in the highly competitive and innovative pharmaceutical industry. That's important to remember as investors examine the upcoming patent cliff for …
BRM
main company
Sharemaestro market context
Trend signal active
52 weeks +49.8% · Next-week setup positive 56.0%
Bristol Myers Squibb (BMY) Stock Looks Reasonable On Earnings Yet Strong Returns Test Value
Bristol-Myers Squibb has delivered a strong 47.9% return over the past year, yet several valuation checks still frame the stock as cheap relative to an intrinsic value estimate and to market multiples. For investors, the question is whether the current share price reflects a …
BRM
main company
Sharemaestro market context
Trend signal active
52 weeks +49.8% · Next-week setup positive 56.0%
Can Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform?
On August 13, two pharmaceutical companies tied to the same cardiovascular research deal delivered major updates. Atrium Therapeutics, Inc. (NASDAQ:RNA) earned a $15 million milestone payment from Bristol-Myers Squibb Company (NYSE:BMY) after delivering a lead RNA compound targeting an undisclosed cardiology indication. The payment …
BRM
main company
Sharemaestro market context
Trend signal active
52 weeks +49.8% · Next-week setup positive 56.0%
Bristol-Myers Squibb (BMY)’s Cellares Exit Raises Questions Over Breyanzi Growth
Bristol-Myers Squibb Company (NYSE:BMY) has ended its partnership with cell-therapy manufacturer Cellares after determining that Cellares' Cell Shuttle platform could not meet the requirements needed to manufacture Breyanzi at commercial scale. The partnership, announced in 2024, was valued at up to $380 million and …
BRM
main company
Sharemaestro market context
Trend signal active
52 weeks +49.8% · Next-week setup positive 56.0%
New FDA Approval Gives Bristol-Myers Squibb (BMY) Another Potential Oncology Growth Catalyst
The U.S. FDA has approved Bristol-Myers Squibb Company (NYSE:BMY)'s oral blood-cancer drug iberdomide, sold as Zenbexus, for patients with relapsed or refractory multiple myeloma. The treatment is given with Johnson & Johnson's Darzalex and dexamethasone. The approval gives BMY another product that could support …
BRM
main company
Sharemaestro market context
Trend signal active
52 weeks +49.8% · Next-week setup positive 56.0%
Can Camzyos' Growth Offset Bristol Myers' Patent Pressures?
Bristol Myers Squibb BMY is banking on label expansion of existing drugs and approval of new drugs to further propel its growth portfolio. Camzyos (mavacamten) is one of the key drugs of this product portfolio. The drug is currently approved in the United States …
BRM
main company
Sharemaestro market context
Trend signal active
52 weeks +49.8% · Next-week setup positive 56.0%
Will ZENBEXUS’s First-in-Class CELMoD Approval Based on MRD-Negative CR Change Bristol Myers Squibb’s (BMY) Narrative
In August 2026, Bristol-Myers Squibb received accelerated FDA approval for ZENBEXUS (iberdomide) as the first cereblon-modulating protein degrader (CELMoD) therapy for adults with relapsed or refractory multiple myeloma after at least one prior treatment including a proteasome inhibitor and an immunomodulatory agent. The approval, …
BRM
main company
Sharemaestro market context
Trend signal active
52 weeks +49.8% · Next-week setup positive 56.0%
What Does Bristol Myers Squibb (BMY) Face After ZENBEXUS Approval And Patent Action?
Bristol Myers Squibb (NYSE:BMY) received FDA approval for ZENBEXUS (iberdomide) in combination therapy for adult patients with relapsed or refractory multiple myeloma, based on minimal residual disease negative complete response. ZENBEXUS is the first FDA approved CELMoD therapy in this multiple myeloma setting, which …
BRM
main company
Sharemaestro market context
Trend signal active
52 weeks +49.8% · Next-week setup positive 56.0%
Bristol-Myers Squibb (BMY) Bets $2.3 Billion on Texas While Eli Lilly (LLY) Wins in the UK
Drugmaker Bristol-Myers Squibb Company (NYSE:BMY) is putting real money behind its confidence in American manufacturing. On August 10, the company said it will spend about $2.3 billion on a new plant in Houston, part of a larger $40 billion U.S. investment pledge. On the …
BRM
main company
Sharemaestro market context
Trend signal active
52 weeks +49.8% · Next-week setup positive 56.0%
Can Eliquis Cushion Bristol Myers' Legacy Portfolio Erosion?
Bristol Myers' BMY legacy portfolio, comprising Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane, continues to face significant erosion from generic competition. Legacy portfolio revenues declined 5% year over year to $10.7 billion in the first half, primarily reflecting the impacts of generic competition for Revlimid, …
BRM
main company
Sharemaestro market context
Trend signal active
52 weeks +49.8% · Next-week setup positive 56.0%
What Could Bristol Myers Squibb (BMY) AI Antibody Deal Mean For Drug Discovery?
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Bristol Myers Squibb (NYSE:BMY) announced a new collaboration with Chai Discovery to advance AI driven therapeutic antibody discovery. The agreement focuses on using …
BRM
main company
Sharemaestro market context
Trend signal active
52 weeks +49.8% · Next-week setup positive 56.0%
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO
Quick Read SPTX's Glyph prodrug platform has generated 24 candidates, with lead asset GlyphAllo entering Phase 2b for MDD and topline results expected in 1H 2027. BMY previously paid $14 billion for Karuna Therapeutics, co-founded by Seaport CEO Daphne Zohar, making it the top-ranked …
BRM
main company
Sharemaestro market context
Trend signal active
52 weeks +49.8% · Next-week setup positive 56.0%
Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery
SAN FRANCISCO, August 20, 2026--(BUSINESS WIRE)--Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with Bristol Myers Squibb to advance the discovery of therapeutic antibodies using artificial intelligence. Under the collaboration, Bristol Myers Squibb will leverage Chai's …
BRM
main company
Sharemaestro market context
Trend signal active
52 weeks +49.8% · Next-week setup positive 56.0%
Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
Hematogenix's proprietary Multiple Myeloma MRD (MM MRD) assay measured the primary efficacy endpoint cited in the FDA-approval of ZENBEXUS (iberdomide), reinforcing Hematogenix's role as a specialized global leader in registrational oncology trials.Hematogenix Log TINLEY PARK, Ill., Aug. 19, 2026 Hematogenix®, a global specialty laboratory …
BRM
main company
Sharemaestro market context
Trend signal active
52 weeks +49.8% · Next-week setup positive 56.0%
Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play
Quick Read AKTS retains full worldwide rights to its alpha-emitting cancer platform, with $517M cash and binary Q1 2027 trial data looming. NVS, whose Pluvicto grew 43% in Q2 2026, and LLY, already a $60M upfront partner, rank as the top two strategic acquirers. …
BRM
main company
Sharemaestro market context
Trend signal active
52 weeks +49.8% · Next-week setup positive 56.0%
What Does Bristol Myers Squibb (BMY) Risk From The Revived $6.7 Billion Lawsuit?
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Bristol Myers Squibb (NYSE:BMY) is facing a revived US$6.7b lawsuit after a federal appeals court reinstated claims tied to its Celgene acquisition. Plaintiffs allege the …
BRM
main company
Sharemaestro market context
Trend signal active
52 weeks +49.8% · Next-week setup positive 56.0%